Hepatocellular carcinoma-linked mutations drive low Wnt/β-catenin activity enabling niche-independent growth and YAP/TAZ signaling.
1/5 보강
AXIN1 organizes assembly of a destruction complex that degrades the transcriptional co-activator β-catenin, thereby preventing inappropriate Wnt/β-catenin signaling.
APA
Venhuizen AJ, van Os Y, et al. (2026). Hepatocellular carcinoma-linked mutations drive low Wnt/β-catenin activity enabling niche-independent growth and YAP/TAZ signaling.. iScience, 29(1), 114501. https://doi.org/10.1016/j.isci.2025.114501
MLA
Venhuizen AJ, et al.. "Hepatocellular carcinoma-linked mutations drive low Wnt/β-catenin activity enabling niche-independent growth and YAP/TAZ signaling.." iScience, vol. 29, no. 1, 2026, pp. 114501.
PMID
41550750 ↗
Abstract 한글 요약
AXIN1 organizes assembly of a destruction complex that degrades the transcriptional co-activator β-catenin, thereby preventing inappropriate Wnt/β-catenin signaling. In hepatocellular carcinoma (HCC), mutations associate with a poor-prognosis subtype distinct from β-catenin-mutant HCC (). To assess how -deficiency drives HCC, we introduced HCC-associated and mutations in human liver cancer cells and liver-derived organoids. We show that mutations activate Wnt/β-catenin signaling to varying but generally lower levels than mutations. Strikingly, premature 5'-end stop codons do not yield knockout mutations but drive alternative translation of N-terminally truncated AXIN1 variants with partial suppressor activity. All variants enable liver progenitor organoids to grow without Wnt and R-spondin, indicating downstream Wnt/β-catenin activation. Additionally, Wnt/β-catenin signaling inversely correlates with YAP/TAZ-mediated signaling, leaving higher YAP/TAZ activity in -mutant versus -mutant cells. Thus, mutations drive physiologically relevant Wnt/β-catenin activation, providing a permissive environment for YAP/TAZ signaling, thereby distinguishing them from mutations.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Microfluidic-based patient-derived organoids recapitulate thyroid cancer heterogeneity and reveal NF-κB-driven maturation for precision therapy.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.